MAP4343|cas:511-26-2|西域试剂

MAP4343,98.09%

产品编号：Bellancom-107116| CAS NO：511-26-2| 分子式：C₂₂H₃₄O₂| 分子量：330.50

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-107116	￥1000.00	杭州北京（现货）
Bellancom-107116	￥1700.00	杭州北京（现货）
Bellancom-107116	￥3500.00	杭州北京（现货）
Bellancom-107116	￥5700.00	杭州北京（现货）
Bellancom-107116	￥9000.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

MAP4343

产品介绍

MAP4343 是 Pregnenolone 的 3-甲基醚衍生物。MAP4343 在体外与微管相关蛋白 2 (MAP2) 结合，刺激微管蛋白的聚合，增强神经突的延伸并保护神经元免受神经毒性剂的侵害。

生物活性

MAP4343 is the 3-methylether derivative of Pregnenolone. MAP4343 binds in vitro to microtubule-associated protein 2 (MAP2), stimulates the polymerization of tubulin, enhances the extension of neurites and protects neurons against neurotoxic agents.

体外研究

MAP4343 (40 μM; 15 or 30 min) stimulates microtubule polymerization in vitro.
MAP4343 (30 μM; 2-8 d) stimulates nerve growth factor (NGF)-induced neurite outgrowth in PC12 cells.
MAP4343 (20 μM; 1 h) protects against microtubule depolymerization induced by Nocodazole in PC12 cells

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

MAP4343 (12 mg/kg; daily s.c. for 28 d) improves the recovery of locomotor function after spinal cord injury (SCI) in rats.
MAP4343 (4 mg/kg; daily s.c. for 6 d) increases MAP2 levels in spinal cord after SCI in rats.
MAP4343 (4 mg/kg; daily s.c. for 6 d) increases the size of lumbar spinal motoneurons' dendrite arbours after SCI in rats.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Adult Sprague-Dawley male rats with spinal cord injury
Dosage:	12 mg/kg
Administration:	Daily s.c. for 28 days
Result:	Increased the number of animals able to walk with weight-supported plantar steps. Showed forelimb-hindlimb coordination at the end of the study.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Adult Sprague-Dawley male rats with spinal cord injury
Dosage:	12 mg/kg
Administration:	Daily s.c. for 28 days
Result:	Increased the number of animals able to walk with weight-supported plantar steps. Showed forelimb-hindlimb coordination at the end of the study.

性状

Solid

溶解性数据

In Vitro:

DMSO : 25 mg/mL (75.64 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	3.0257 mL	15.1286 mL	30.2572 mL
5 mM	0.6051 mL	3.0257 mL	6.0514 mL
10 mM	0.3026 mL	1.5129 mL	3.0257 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: 2.5 mg/mL (7.56 mM); Suspended solution; Need ultrasonic

此方案可获得 2.5 mg/mL (7.56 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.5 mg/mL (7.56 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (7.56 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。